The Europe Genetic Toxicology Testing Market would witness market growth of 12.5% CAGR during the forecast period (2022-2028).
The costs and duration of genetic toxicology testing are expected to change as there is an increased emphasis on reducing the use of animals in the process of evaluating a substance's genotoxic potential. These shifts in the testing market's dynamics are anticipated to create new in-vitro testing opportunities and significantly increase market activity.
To support the increased demand for innovative treatments, Inotiv Inc. said that it will keep expanding its capacity to conduct genetic toxicology research for bacterial and in vitro cytogenetics testing. As cancer research has advanced, anticancer medications are now often employed to treat a variety of human malignancies. Chemotherapy is typically given to a substantial percentage of patients suffering from advanced cancer as part of treatment.
Genotoxic chemotherapy is a form of cancer treatment that involves the use of one or more genotoxic medicines to kill cancer cells by causing DNA damage to them. The majority of chemotherapeutic medications, it has been demonstrated, do not only harm tumor cells; they can also target normal cells, which can result in a wide spectrum of serious adverse responses. Since cancer cells divide quickly, they are very sensitive to medication therapy.
There is currently a phase of reappraisal for genetic toxicity and its function in the identification of carcinogens. The three R's formula that stands for reduction, refinement, and replacement are the cornerstones of national and EU animal protection laws, and there is growing interest in the development of alternatives to animal testing. The EU Cosmetics Directive's Seventh Amendment forbids the marketing of cosmetic and personal care products with components that have undergone animal testing. But the directive states that it is compulsory for every component of the product to be assessed for toxicity.
The Germany market dominated the Europe Genetic Toxicology Testing Market by Country in 2021; thereby, achieving a market value of $154 million by 2028. The UK market is exhibiting a CAGR of 11.6% during (2022 - 2028). Additionally, The France market would experience a CAGR of 13.3% during (2022 - 2028).
Based on Product, the market is segmented into Services, Reagents & Consumables and Assays. Based on Type, the market is segmented into In Vitro and In Vivo. Based on Application, the market is segmented into Pharmaceutical & Biotechnology, Food Industry, Cosmetics Industry and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Genetic Toxicology Testing Market will Hit $2.4 Billion by 2028, at a CAGR of 13.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific Group, Jubilant Pharmova Limited., Syngene International Limited, Gentronix Ltd., Inotiv Inc., Creative Bioarray and MB Research Laboratories.
By Product
By Type
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 